Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07283094 · ClinicalTrials.gov registry record · Phase 1

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by Montefiore Medical Center.

Recruiting
Registry status
Phase 1
Development phase
33
Enrollment target
1
Study location

NCT07283094 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 33 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07283094, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, is actively recruiting participants, sponsored by Montefiore Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1, uncontrolled, single-arm, open-label, nonrandomized, dose escalation, study of Decitabine (DAC)+Venetoclax (VEN)+FHD-286 in participants with newly diagnosed Acute Myeloid Leukemia (AML) classified as adverse risk per the 2022 European Leukemia Net (ELN) criteria or AML that has progressed after one prior line of therapy.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndrome

Interventions

  • DRUG Venetoclax
  • DRUG Decitabine
  • DRUG FHD-286

Study Locations (1)

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2026-02-03
Est. Completion 2030-02
Phase Phase 1

Sponsor

Montefiore Medical Center

345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07283094

The ClinicalTrials.gov registry entry for NCT07283094 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (72% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT07283094 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT07283094 about?

NCT07283094 is a clinical study titled "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia". This is a Phase 1, uncontrolled, single-arm, open-label, nonrandomized, dose escalation, study of Decitabine (DAC)+Venetoclax (VEN)+FHD-286 in participants with newly diagnosed Acute Myeloid Leukemia (AML) classified as adverse risk per the 2022 European Leukemia Net (ELN) criteria or AML that has p...

What is the current status of trial NCT07283094?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2026-02-03. Estimated completion is 2030-02.

What conditions does trial NCT07283094 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome.

What interventions are being tested in trial NCT07283094?

The interventions under investigation include: Venetoclax (DRUG), Decitabine (DRUG), FHD-286 (DRUG).

Who is sponsoring clinical trial NCT07283094?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07283094 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndrome

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.